Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus MR4 Extension Study for GVHD Prophylaxis
NCT00189748Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Aug 2004
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tacrolimus in graft-versus-host disease (GVHD), sponsored by Astellas Pharma. Started Aug 2004; status: completed.
02
Drugs
tacrolimus
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT00189748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00189748.